Bone Medical's level one ADR program granted
Monday, 08 August, 2005
Bone Medical (ASX:BNE) has received approval for a level one American Depository Receipt (ADR) program with receipts tradable in the over-the-counter market under the code BMEDY.
The Bank of New York will serve as the depositary bank.
"The ADR program will allow US investors to purchase Bone Medical stock from their local stockbroker, broaden Bone Medical's shareholder base and allow our shares to be traded in the same arena as our global peers," said Bone Medical's CEO Michael Redman in a statement. "Furthermore, the ADR program allows investment by institutions that are only permitted to buy US-based securities."
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
